Member Info for stocksaint

Looks to me like 43p is key resistance to scale....

Lloydf,

"these will go back down to 25p in the short term"

Any other reason you think this, other than it being an AIM share lol?

Manolo,

I just invested £20k today for first time. Looks like a decent punt. When do you think they'll enter profitability?

I don't see anything positive happening here for shareholders for a while now. I just put £20k into Futura Medical. They did trading update today. I thought worth a punt.

My understanding is GDR only hoping to get greenlight to rollout stroke marker in Manchester area at the moment anyway. The write-up from NICE will say more testing needs to be done etc. My guess is latest delay is due to scheduling issues and manpower of people on committee etc. GDR made it clear the big short term hope was getting funding to progress FDA. To me this is the important outstanding piece of news at the moment. But I thought we would of heard something by now on this front.....

Found it interesting to listen to the presentation again, the outlook statements on youtube, with the script on (essentially youtube subtitles.) He doesn't contradict anything in the results RNS, but he does put a bit of a gloss on things, as you would expect for what is essentially a salesy presentation. The bit where he says he's 100% sure specialist commissioning will happen is slightly amusing. As within seconds he qualifies by saying he'll be speaking to loads of people to make it happen etc. Because obviously it's not his decision whether NHS England decides to to go for specialist commissioning or not and they haven't even held public consultation yet.

Relistening to presentation JLC, both figures are actually correct on cash burn, shown on slide 15. Cash burn is £400k per month, but if the R&D tax credit is deducted from that, it falls to £327k. So actual cash burn is £400k per month, but adjusted cash burn is £327k per month. In other words, its £400k until the point when they receive the tax credit, and then it's not if you factor that in. lol

But they do need really big year-on-year percentage sales growth just to breakeven....

Yes Nissan, must be at least partly due to RF background selling. Guess they'll be another drawdown at the end of the week or early next week as volume has mostly been good.

It's strange that people seem to quote things from the presentation that appear to contradict the results RNS that was released one day before! I'll have to listen that presentation again. I'm wondering maybe if I didn't listen all the way through last time??

JLC, They've consistently said the cashburn is 400k per month. Where did you get 327k from??

NICE full validation????

Doesn't sound right. Previously NICE said they were going to need 3 years of data.

When I listened to the presentation they sounded very downbeat about NICE

If he said "January" about news, perhaps he was alluding to the extended rollout of Sussex trust following Brighton announcement. When that LinkedIn post appeared earlier this month, made me think that GDR would have preferred to announce that themselves. However, the LinkedIn post by someone from the trust didn't make it clear how many NICU units in the trust would be adopting straightaway. i.e. all of them or just a few.

In the results it was basically alluding to a placing, mainly in guise to fund US clearance and launch over there. To me that meant better to buy after funding announced. So that's what I've been waiting for. I too felt that meant January. But the first thing they did early this month is just pull off another drawdown from RF.

What EXACTLY what the wording of the this by "the end of January" pledge anyway. A line from the presentation?

Roger,

It was cleared up way back that this was going to be a De Novo case, as there's no comparable test in US market. In any case, the actual fees charged by FDA are always virtually immaterial. The big money gets spent on the proof they require on US soil.

Roger,

"cost of De Novo and 510k routes are far cheaper"

Post some evidence of this. GDR said it would cost about £2m a couple of years ago, and I can't see much has changed. It will probably cost more than that given inflation.

Stockpick,

They way I view it, news on FDA progress would be tied to a placing. I expect minimum £2m will be needed to finance the beginning of a venture into US market, and to secure FDA approval (not actual fees to FDA, but actual testing the product out on US soil, which FDA pretty much always requires).

Some bureaucracy yes, but it's possible GDR weren't very clever about their strategy. Why did it suddenly end up in a hazy EVA process? And why didn't they just go for specialist commissioning earlier? I suspect didn't bother getting advice from market access/regulatory consultants ahead of time.

God knows. But NICE does have a tendency to rereview the same thing every 3 years.